Dr Reddys Laboratories shares gained 2.17% in Tuesday's early trading session, reaching a price of Rs 1,277.80 at 09:24 am. The stock is a constituent of the Nifty 50 index.
Consolidated Quarterly Financials:
The following table summarizes the consolidated quarterly income statement of Dr Reddys Laboratories:
| Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | |
|---|---|---|---|---|---|
| Sales | Rs 8,572.10 Crore | Rs 8,528.40 Crore | Rs 8,381.20 Crore | Rs 8,038.20 Crore | Rs 7,696.10 Crore |
| Other Income | Rs 290 Crore | Rs 522 Crore | Rs 150 Crore | Rs 307 Crore | Rs 187 Crore |
| Total Income | Rs 8,862 Crore | Rs 9,050 Crore | Rs 8,531 Crore | Rs 8,345 Crore | Rs 7,883 Crore |
| Total Expenditure | Rs 6,874 Crore | Rs 6,985 Crore | Rs 6,579 Crore | Rs 6,358 Crore | Rs 5,946 Crore |
| EBIT | Rs 1,987 Crore | Rs 2,065 Crore | Rs 1,951 Crore | Rs 1,987 Crore | Rs 1,936 Crore |
| Interest | Rs 83 Crore | Rs 65 Crore | Rs 81 Crore | Rs 75 Crore | Rs 59 Crore |
| Tax | Rs 495 Crore | Rs 418 Crore | Rs 470 Crore | Rs 575 Crore | Rs 490 Crore |
| Net Profit | Rs 1,409.70 Crore | Rs 1,581.20 Crore | Rs 1,400.00 Crore | Rs 1,335.80 Crore | Rs 1,386.50 Crore |
The revenue for the quarter ending June 2025 stood at Rs 8,572.10 Crore, a slight increase compared to Rs 8,528.40 Crore for the quarter ending March 2025. The net profit for the quarter ending June 2025 was Rs 1,409.70 Crore, while the quarter ending March 2025 saw a net profit of Rs 1,581.20 Crore.
Consolidated Yearly Financials:
The following table summarizes the consolidated yearly income statement of Dr Reddys Laboratories:
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Sales | Rs 32,643.90 Crore | Rs 28,011.10 Crore | Rs 24,669.70 Crore | Rs 21,545.20 Crore | Rs 19,047.50 Crore |
| Other Income | Rs 1,097 Crore | Rs 894 Crore | Rs 1,055 Crore | Rs 484 Crore | Rs 291 Crore |
| Total Income | Rs 33,741 Crore | Rs 28,905 Crore | Rs 25,725 Crore | Rs 22,029 Crore | Rs 19,338 Crore |
| Total Expenditure | Rs 25,800 Crore | Rs 21,548 Crore | Rs 19,570 Crore | Rs 18,942 Crore | Rs 16,406 Crore |
| EBIT | Rs 7,940 Crore | Rs 7,357 Crore | Rs 6,154 Crore | Rs 3,086 Crore | Rs 2,932 Crore |
| Interest | Rs 282 Crore | Rs 171 Crore | Rs 142 Crore | Rs 95 Crore | Rs 97 Crore |
| Tax | Rs 1,954 Crore | Rs 1,623 Crore | Rs 1,541 Crore | Rs 878 Crore | Rs 931 Crore |
| Net Profit | Rs 5,703.50 Crore | Rs 5,563.20 Crore | Rs 4,470.30 Crore | Rs 2,112.20 Crore | Rs 1,903.60 Crore |
The revenue for the year ending March 2025 was Rs 32,643.90 Crore, an increase from the Rs 28,011.10 Crore reported for the year ending March 2024. Net profit also increased from Rs 5,563.20 Crore in March 2024 to Rs 5,703.50 Crore in March 2025.
Consolidated Balance Sheet:
The following table presents the consolidated balance sheet of Dr Reddys Laboratories:
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Share Capital | Rs 83 Crore | Rs 83 Crore | Rs 83 Crore | Rs 83 Crore | Rs 83 Crore |
| Reserves & Surplus | Rs 33,466 Crore | Rs 28,171 Crore | Rs 23,202 Crore | Rs 19,129 Crore | Rs 17,558 Crore |
| Current Liabilities | Rs 13,033 Crore | Rs 9,588 Crore | Rs 8,572 Crore | Rs 9,765 Crore | Rs 8,103 Crore |
| Other Liabilities | Rs 2,843 Crore | Rs 1,021 Crore | Rs 426 Crore | Rs 768 Crore | Rs 871 Crore |
| Total Liabilities | Rs 49,426 Crore | Rs 38,863 Crore | Rs 32,285 Crore | Rs 29,746 Crore | Rs 26,616 Crore |
| Fixed Assets | Rs 19,378 Crore | Rs 11,294 Crore | Rs 9,701 Crore | Rs 8,867 Crore | Rs 9,210 Crore |
| Current Assets | Rs 25,018 Crore | Rs 24,805 Crore | Rs 20,425 Crore | Rs 17,782 Crore | Rs 14,550 Crore |
| Other Assets | Rs 5,030 Crore | Rs 2,763 Crore | Rs 2,157 Crore | Rs 3,097 Crore | Rs 2,855 Crore |
| Total Assets | Rs 49,426 Crore | Rs 38,863 Crore | Rs 32,285 Crore | Rs 29,746 Crore | Rs 26,616 Crore |
| Contingent Liabilities | Rs 1,738 Crore | Rs 2,091 Crore | Rs 997 Crore | Rs 936 Crore | Rs 1,077 Crore |
The following table shows the consolidated cash flow statement:
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Operating Activities | Rs 4,642 Crore | Rs 4,543 Crore | Rs 5,887 Crore | Rs 2,810 Crore | Rs 3,570 Crore |
| Investing Activities | Rs -5,807 Crore | Rs -4,028 Crore | Rs -4,137 Crore | Rs -2,638 Crore | Rs -2,266 Crore |
| Financing Activities | Rs 1,891 Crore | Rs -376 Crore | Rs -2,686 Crore | Rs -242 Crore | Rs -29 Crore |
| Others | Rs 22 Crore | Rs -5 Crore | Rs 28 Crore | Rs 73 Crore | Rs 11 Crore |
| Net Cash Flow | Rs 748 Crore | Rs 132 Crore | Rs -907 Crore | Rs 3 Crore | Rs 1,285 Crore |
The Basic Earnings per Share (EPS) stood at Rs 67.89 as of March 2025, compared to Rs 335.22 in March 2024. The Return on Networth/Equity was 16.85% in March 2025, while it was 19.74% in March 2024. The debt to equity ratio stood at 0.12 as of March 2025.
Corporate Actions:
- Bonus Issues: The company has a history of bonus issues, including a 1:1 bonus on May 31, 2006, with an ex-bonus date of August 28, 2006.
- Stock Splits: Dr Reddys Laboratories has split its stock, with the latest split occurring on July 27, 2024, which changed the face value from Rs 5 to Rs 1, effective from October 28, 2024.
- Dividends: The company announced a final dividend of Rs 8 per share on May 9, 2025, with the ex-date being July 10, 2025.
Moneycontrol analysis indicates a bullish sentiment on the stock as of September 2, 2025.
With the stock currently trading at Rs 1,277.80, Dr Reddys Laboratories has demonstrated a positive start in today's session, driven by a rise of 2.17%.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
